|
Genzyme Corporation is an American biotechnology company based in Cambridge, Massachusetts. Since its acquisition in 2011, Genzyme has been a fully owned subsidiary of Sanofi. In 2010 Genzyme was the world’s third-largest biotechnology company, employing more than 11,000 people around the world. As a subsidiary of Sanofi, Genzyme has a presence in approximately 65 countries, including 17 manufacturing facilities and 9 genetic-testing laboratories, its products are sold in 90 countries. In 2007, Genzyme generated $3.8 billion in revenues with more than 25 products in the market. In 2006 and 2007 Genzyme was named one of Fortune Magazine’s “100 Best Companies to Work for”. The company donated $83 million worth of products worldwide; in 2006, it made $11 million in cash donations. In 2005, Genzyme was awarded the National Medal of Technology, the highest level of honor awarded by the president of the United States to America’s leading innovators. ==History== The company was started by Sheridan Snyder and George M. Whitesides in 1981. Genzyme's scientific founder was Henry Blair who had a contract with the National Institutes of Health (NIH) to produce modified enzymes for the NIH to test in clinical trials. Blair was a technician at the New England Enzyme Center at Tufts Medical School.〔 Genzyme's first office was an old clothing warehouse adjacent to Tufts Medical School.〔 Henry Termeer joined Genzyme as its president in 1983 and worked to redirect the company, which by this time had reached a valuation of , from its focus on diagnostic enzymes to modified enzymes for use as human therapeutics. In 1984, Robin Berman, MD, who volunteered at the NIH, had a three-year-old son Brian, who had Gaucher's disease. He was scheduled for a spleen removal but his mother pleaded with Roscoe Brady, MD an expert in Gaucher's disease to include Brian in the clinical trial of Ceredase along with the other seven patients who were all adults. This trial ultimately failed due to use of too low a dose of the enzyme, but Ceredase went n to "become the company's most important product line", receiving FDA approval in 1991〔 In 1985, Termeer became the company's Chief executive officer (CEO), and in 1986 he took the company public.〔 Following the approval and success of Ceredase, Genzyme became devoted to finding drugs, involving recombinant human enzymes,〔 that would cure enzyme deficiency conditions that were essential to human survival and which usually afflict a very small percentage of the world’s population. Drugs used to treat such conditions are considered to be “orphan drugs.” Genzyme acquired several of Impath's laboratories and cancer-testing technologies in May 2004, after Impath sought Chapter 11 bankruptcy protection. In 2010, the year before the company's acquisition by Sanofi-Aventis, Genzyme had more than in net income on revenue of $4 billion and was the fourth-largest American biopharmaceutical company.〔 By this time, enzyme therapies accounted for about 40% of revenues, a portfolio managed by the "Personalized Genetic Health" unit, the largest of five operating units.〔 抄文引用元・出典: フリー百科事典『 ウィキペディア（Wikipedia）』 ■ウィキペディアで「Genzyme Corporation is an American biotechnology company based in Cambridge, Massachusetts. Since its acquisition in 2011, Genzyme has been a fully owned subsidiary of Sanofi. In 2010 Genzyme was the world’s third-largest biotechnology company, employing more than 11,000 people around the world. As a subsidiary of Sanofi, Genzyme has a presence in approximately 65 countries, including 17 manufacturing facilities and 9 genetic-testing laboratories, its products are sold in 90 countries. In 2007, Genzyme generated $3.8 billion in revenues with more than 25 products in the market. In 2006 and 2007 Genzyme was named one of Fortune Magazine’s “100 Best Companies to Work for”. The company donated $83 million worth of products worldwide; in 2006, it made $11 million in cash donations. In 2005, Genzyme was awarded the National Medal of Technology, the highest level of honor awarded by the president of the United States to America’s leading innovators.==History==The company was started by Sheridan Snyder and George M. Whitesides in 1981. Genzyme's scientific founder was Henry Blair who had a contract with the National Institutes of Health (NIH) to produce modified enzymes for the NIH to test in clinical trials. Blair was a technician at the New England Enzyme Center at Tufts Medical School. Genzyme's first office was an old clothing warehouse adjacent to Tufts Medical School.Henry Termeer joined Genzyme as its president in 1983 and worked to redirect the company, which by this time had reached a valuation of , from its focus on diagnostic enzymes to modified enzymes for use as human therapeutics.In 1984, Robin Berman, MD, who volunteered at the NIH, had a three-year-old son Brian, who had Gaucher's disease. He was scheduled for a spleen removal but his mother pleaded with Roscoe Brady, MD an expert in Gaucher's disease to include Brian in the clinical trial of Ceredase along with the other seven patients who were all adults. This trial ultimately failed due to use of too low a dose of the enzyme, but Ceredase went n to "become the company's most important product line", receiving FDA approval in 1991In 1985, Termeer became the company's Chief executive officer (CEO), and in 1986 he took the company public.Following the approval and success of Ceredase, Genzyme became devoted to finding drugs, involving recombinant human enzymes, that would cure enzyme deficiency conditions that were essential to human survival and which usually afflict a very small percentage of the world’s population. Drugs used to treat such conditions are considered to be “orphan drugs.”Genzyme acquired several of Impath's laboratories and cancer-testing technologies in May 2004, after Impath sought Chapter 11 bankruptcy protection.In 2010, the year before the company's acquisition by Sanofi-Aventis, Genzyme had more than in net income on revenue of $4 billion and was the fourth-largest American biopharmaceutical company. By this time, enzyme therapies accounted for about 40% of revenues, a portfolio managed by the "Personalized Genetic Health" unit, the largest of five operating units.」の詳細全文を読む スポンサード リンク
|